ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT02453282
Brief Title: Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). (MYSTIC)

First Submitted : May 20, 2015
First Submitted that Met QC Criteria : May 22, 2015
First Posted : May 25, 2015 (Estimate)

Last Update Submitted that Met QC Criteria : September 6, 2018
Last Update Posted : September 7, 2018